Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(10%)
Results Posted
0%(0 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_2
2
20%
Ph not_applicable
2
20%
Ph phase_1
1
10%
Ph phase_3
3
30%
Ph phase_4
2
20%

Phase Distribution

1

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
2(20.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)
Other(6)

Detailed Status

unknown6
Terminated2
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
33.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 22 (20.0%)
Phase 33 (30.0%)
Phase 42 (20.0%)
N/A2 (20.0%)

Trials by Status

completed110%
terminated220%
unknown660%
active_not_recruiting110%

Recent Activity

1 active trials
Showing 5 of 10
completedphase_2

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

NCT05322330
active_not_recruitingphase_3

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

NCT04296175
terminatedphase_2

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

NCT02043587
unknownphase_1

Targeting the Tumor Microenvironment in R/M SCCHN

NCT03844763
unknownphase_4

PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

NCT03689465
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05322330Phase 2

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Completed
NCT04296175Phase 3

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

Active Not Recruiting
NCT02043587Phase 2

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Terminated
NCT03844763Phase 1

Targeting the Tumor Microenvironment in R/M SCCHN

Unknown
NCT03689465Phase 4

PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

Unknown
NCT03949634Phase 3

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

Unknown
NCT02294344Not Applicable

The Clinical Efficacy of DFPP in Patients With AAGN

Terminated
NCT02572596Not Applicable

Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients

Unknown
NCT03006614Phase 3

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

Unknown
NCT01873807Phase 4

HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10